Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence - PubMed (original) (raw)

. 2006 Dec 1;66(23):11341-7.

doi: 10.1158/0008-5472.CAN-06-1570.

Lucia Gullotti, Lukas Carl Heukamp, Susanne Wolf, Nicolaus Friedrichs, Roland Vorreuther, Gerold Solleder, Patrick J Bastian, Jörg Ellinger, Eric Metzger, Roland Schüle, Reinhard Buettner

Affiliations

• PMID: 17145880
• DOI: 10.1158/0008-5472.CAN-06-1570

Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence

Philip Kahl et al. Cancer Res. 2006.

Abstract

Prostate cancer biology varies from locally confined tumors with low risk for relapse to tumors with high risk for progression even after radical prostatectomy. Currently, there are no reliable biomarkers to predict tumor relapse and poor clinical outcome. In this study, we correlated expression patterns of the androgen receptor (AR) coactivators lysine-specific histone demethylase 1 (LSD1) and four and a half LIM-domain protein 2 (FHL2), AR, Gleason score, Gleason grade, and p53 expression in clinically organ confined prostate cancers with relapse after radical prostatectomy. Our data reveal that high levels of LSD1, nuclear expression of the FHL2 coactivator, high Gleason score and grade, and very strong staining of nuclear p53 correlate significantly with relapse during follow-up. No correlation exists with relapse and the expression of AR and cytoplasmic expression of FHL2. To confirm these data, we did quantitative reverse transcription-PCR and Western blot analyses in a subset of tumor specimens. Consistently, both LSD1 mRNA and protein levels were significantly up-regulated in high-risk tumors. We previously identified LSD1 and FHL2 as nuclear cofactors interacting specifically with the AR in prostate cells and showed that both stimulate androgen-dependent gene transcription. Our present study suggests that LSD1 and nuclear FHL2 may serve as novel biomarkers predictive for prostate cancer with aggressive biology and point to a role of LSD1 and FHL2 in constitutive activation of AR-mediated growth signals.

PubMed Disclaimer

Similar articles

• Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.
  Heemers HV, Regan KM, Dehm SM, Tindall DJ. Heemers HV, et al. Cancer Res. 2007 Nov 1;67(21):10592-9. doi: 10.1158/0008-5472.CAN-07-1917. Cancer Res. 2007. PMID: 17975004
• Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression.
  Wissmann M, Yin N, Müller JM, Greschik H, Fodor BD, Jenuwein T, Vogler C, Schneider R, Günther T, Buettner R, Metzger E, Schüle R. Wissmann M, et al. Nat Cell Biol. 2007 Mar;9(3):347-53. doi: 10.1038/ncb1546. Epub 2007 Feb 4. Nat Cell Biol. 2007. PMID: 17277772
• Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate.
  Kinoshita M, Nakagawa T, Shimizu A, Katsuoka Y. Kinoshita M, et al. Int J Urol. 2005 Apr;12(4):390-7. doi: 10.1111/j.1442-2042.2005.01093.x. Int J Urol. 2005. PMID: 15948728
• Expression and function of androgen receptor coactivators in prostate cancer.
  Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Culig Z, et al. J Steroid Biochem Mol Biol. 2004 Nov;92(4):265-71. doi: 10.1016/j.jsbmb.2004.10.003. Epub 2004 Dec 19. J Steroid Biochem Mol Biol. 2004. PMID: 15663989 Review.
• New roles of flavoproteins in molecular cell biology: histone demethylase LSD1 and chromatin.
  Forneris F, Battaglioli E, Mattevi A, Binda C. Forneris F, et al. FEBS J. 2009 Aug;276(16):4304-12. doi: 10.1111/j.1742-4658.2009.07142.x. Epub 2009 Jul 14. FEBS J. 2009. PMID: 19624733 Review.

Cited by

• The emerging role of histone lysine demethylases in prostate cancer.
  Crea F, Sun L, Mai A, Chiang YT, Farrar WL, Danesi R, Helgason CD. Crea F, et al. Mol Cancer. 2012 Aug 6;11:52. doi: 10.1186/1476-4598-11-52. Mol Cancer. 2012. PMID: 22867098 Free PMC article. Review.
• LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer.
  Ding J, Zhang ZM, Xia Y, Liao GQ, Pan Y, Liu S, Zhang Y, Yan ZS. Ding J, et al. Br J Cancer. 2013 Aug 20;109(4):994-1003. doi: 10.1038/bjc.2013.364. Epub 2013 Jul 30. Br J Cancer. 2013. PMID: 23900215 Free PMC article.
• Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives.
  Song Y, Wu F, Wu J. Song Y, et al. J Hematol Oncol. 2016 Jun 17;9(1):49. doi: 10.1186/s13045-016-0279-9. J Hematol Oncol. 2016. PMID: 27316347 Free PMC article. Review.
• Design Two Novel Tetrahydroquinoline Derivatives against Anticancer Target LSD1 with 3D-QSAR Model and Molecular Simulation.
  Xu Y, Fan B, Gao Y, Chen Y, Han D, Lu J, Liu T, Gao Q, Zhang JZ, Wang M. Xu Y, et al. Molecules. 2022 Nov 30;27(23):8358. doi: 10.3390/molecules27238358. Molecules. 2022. PMID: 36500451 Free PMC article.
• Deficiency of the LIM-only protein FHL2 reduces intestinal tumorigenesis in Apc mutant mice.
  Labalette C, Nouët Y, Levillayer F, Colnot S, Chen J, Claude V, Huerre M, Perret C, Buendia MA, Wei Y. Labalette C, et al. PLoS One. 2010 Apr 28;5(4):e10371. doi: 10.1371/journal.pone.0010371. PLoS One. 2010. PMID: 20442768 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal